inactivated japanese encephalitis vaccine
Trade name: Ixiaro
Vaccineapproved
Approved
Mar 30, 2009
Japanese encephalitis vaccine is a vaccine that protects against Japanese encephalitis. The vaccines are more than 90% effective. The duration of protection with the vaccine is not clear but its effectiveness appears to decrease over time. Doses are given either by injection into a muscle or just under the skin. — Wikipedia
Clinical trial activity
55 trials · 48 clinical orgs · 2 marketing orgs
Phase 1
4
Phase 2
39
Phase 3
27
Phase 4
13
Earliest trial started Aug 1, 2002 (NCT00694460)
Timeline
Indications
Approved for
Studied for
- Chickenpox · Phase 3
- Communicable Diseases · Phase 2
- Dengue · Phase 2
- Dengue Virus · Phase 2
- Encephalitis · Phase 3
- Encephalitis, Japanese · Phase 4
- Healthy Volunteers · Phase 4
- Hepatitis A · Phase 3
- Immune System Diseases · Phase 4
- Japanese Encephalitis Vaccines · Phase 4
- Measles · Phase 4
- Meninges · Phase 3
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 3
- Mumps · Phase 4
- Pre-Exposure Prophylaxis · Phase 2
- Rabies · Phase 3
- Rubella · Phase 4
- Severe Dengue · Phase 2
- Typhoid Fever · Phase 3
- Vaccine-Preventable Diseases · Phase 4
- Vaccines · Phase 4
- Virus Diseases · Phase 2
- Yellow Fever · Phase 3
- Zika Virus Infection · Phase 1
Mechanism of action
- Japanese encephalitis virusImmunity, active
Japanese encephalitis virus immunity, active
Approval history
- approvedMar 30, 2009
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaJapanese encephalitis vaccine ↗
- NCATS2V2JJ0S00T ↗
Also known as
- cd-jev
- ic51
- inactivated japanese encephalitis vaccine
- ixiaro
- ixiaro
- japanese encephalitis chimeric virus vaccine
- japanese encephalitis purified inactivated vaccine
- japanese encephalitis vaccine
- japanese encephalitis vaccine, inactivated, adsorbed
- japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells)
- japanese encephalitis virus vaccine
- je vaccine
- je-vax
- jev vaccine
- mb-jev
- sa-14-14-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680128 | Phase 1/Phase 2 (Phase 2) | Feb 20, 2025 | SK Bioscience Co., Ltd. |
| NCT06678373 | Phase 4 | Nov 1, 2024 | Government of China, Liaoning Chengda |
| NCT06331702 | Phase 4 | Mar 2, 2024 | Liaoning Chengda |
| NCT06825312 | Phase 4 | Nov 11, 2023 | Government of China, Liaoning Chengda |
| NCT06027801 | N/A | Sep 6, 2023 | Government of Thailand, Mahidol University, University of Oxford |
| NCT05568953 | Phase 2 | Oct 31, 2022 | Duke University, Singapore General Hospital |
| NCT04817917 | Phase 4 | Mar 1, 2021 | Government of China, Liaoning Chengda |
| NCT03971058 | Phase 4 | Mar 1, 2019 | Medical University of Vienna, Valneva |
| NCT03282370 | Phase 3 | Sep 30, 2017 | Government of Vietnam |
| NCT03204227 | Phase 2 | Jun 2, 2017 | Government of Vietnam |
| NCT02963909 | Phase 1 | Nov 1, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02880865 | Phase 4 | Oct 1, 2016 | DF/Net Research, INC Research, PATH |
| NCT04223037 | Phase 3 | Sep 1, 2015 | Chinese Academy of Medical Sciences, Inner Mongolia Autonomous Region Center for Diseases Prevention and Control (IMCDC) |
| NCT02643433 | Phase 4 | Aug 1, 2015 | Centers for Disease Control and Prevention (CDC), Centers for Disease Control and Prevention, China, Government of China |
| NCT02532569 | Phase 4 | Aug 1, 2015 | Boryung Pharmaceutical Company |
| NCT02514746 | Phase 4 | Jul 1, 2015 | International Center for Diarrheal Disease Research, PATH |
| NCT02816554 | Phase 2 | Apr 1, 2015 | Government of Vietnam |
| NCT02367664 | Phase 3 | Oct 1, 2014 | Government of China, Shandong Hengye Biotech Co., Ltd. |
| NCT01954810 | Phase 4 | Oct 1, 2013 | KhonKaen University |
| NCT01943305 | Phase 2 | Oct 1, 2013 | Duke University, Singapore General Hospital |
Showing 20 of 55 trials
Page 1 / 3
Organizations
Research & Development (48)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Valneva | For profit | 16 | 15 | 3 | 2005 |
| Sanofi | For profit | 10 | 10 | 2 | 2005 |
| Government of China | Government | 5 | 2 | 2 | 2014 |
| Liaoning Chengda | Government | 4 | 3 | 1 | 2021 |
| Novartis | For profit | 4 | 4 | 2 | 2002 |
| Government of Vietnam | Government | 3 | 3 | 2 | 2015 |
| Sanofi-Aventis | For profit | 3 | 0 | 2 | 2008 |
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 2 | 2010 |
| Duke University | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Government of Thailand | Government | 2 | 0 | 2 | 2003 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 2 | 1 | 1 | 2012 |
| Mahidol University | Academic/Hospital | 2 | 1 | 2 | 2010 |
| Medical University of Vienna | Academic/Hospital | 2 | 1 | 1 | 2010 |
| PATH | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Singapore General Hospital | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Azad University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 0 | 1 | 2015 |
| Centers for Disease Control and Prevention, China | Government | 1 | 1 | 1 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2015 |
48 organizations
Page 1 / 3